Clinical Trial Update: Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the antidiabetic drug dapagliflozin on coronary vascular function in patients with Type 2 diabetes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: Centre Hospitalier Universitaire Saint Pierre | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: TERMINATED